Daniel E Weiner1, Hocine Tighiouart2, Vladimir Ladik3, Klemens B Meyer4, Philip G Zager5, Douglas S Johnson6. 1. William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, MA. Electronic address: dweiner@tuftsmedicalcenter.org. 2. Biostatistics Research Center, Boston, MA. 3. Dialysis Clinic Inc, Winnetka, IL. 4. William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, MA. 5. Dialysis Clinic Inc, Albuquerque, NM. 6. Dialysis Clinic Inc, Nashville, TN.
Abstract
BACKGROUND: Hemodialysis patients have high mortality rates, potentially reflecting underlying comorbid conditions and ongoing catabolism. Intradialytic oral nutritional supplements may reduce this risk. STUDY DESIGN: Retrospective propensity-matched cohort. SETTING & PARTICIPANTS: Maintenance hemodialysis patients treated at Dialysis Clinic Inc facilities who were initiated on a nutritional supplement protocol in September to October 2010 were matched using a propensity score to patients at facilities at which the protocol was not used. PREDICTORS: Prescription of the protocol, whereby hemodialysis patients with serum albumin levels ≤3.5g/dL would initiate oral protein supplementation during the dialysis procedure. Sensitivity analyses matched on actual supplement intake during the first 3 study months. Covariates included patient and facility characteristics, which were used to develop the propensity scores and adjust multivariable models. OUTCOMES: All-cause mortality, ascertained though March 2012. RESULTS: Of 6,453 eligible patients in 101 eligible hemodialysis facilities, the protocol was prescribed to 2,700, and 1,278 of these were propensity matched to controls. Mean age was 61 ± 15 (SD) years and median dialysis vintage was 34 months. There were 258 deaths among protocol assignees versus 310 among matched controls during a mean follow-up of 14 months. In matched analyses, protocol prescription was associated with a 29% reduction in the hazard of all-cause mortality (HR, 0.71; 95% CI, 0.58-0.86); adjustment had minimal impact on models. In time-dependent models incorporating change in albumin level, protocol status remained significant but was attenuated in models incorporating a 30-day lag. Similar results were seen in sensitivity analyses of 439 patients receiving supplements who were propensity-matched to controls, with 116 deaths among supplement users versus 140 among controls (HR, 0.79; 95% CI, 0.60-1.05), achieving statistical significance in adjusted models. LIMITATIONS: Observational design, potential residual confounding. CONCLUSIONS: Prescription of an oral nutritional supplement protocol and use of oral protein nutritional supplements during hemodialysis are associated with reduced mortality among in-center maintenance hemodialysis patients, an effect likely not mediated by change in serum albumin levels.
BACKGROUND: Hemodialysis patients have high mortality rates, potentially reflecting underlying comorbid conditions and ongoing catabolism. Intradialytic oral nutritional supplements may reduce this risk. STUDY DESIGN: Retrospective propensity-matched cohort. SETTING & PARTICIPANTS: Maintenance hemodialysis patients treated at Dialysis Clinic Inc facilities who were initiated on a nutritional supplement protocol in September to October 2010 were matched using a propensity score to patients at facilities at which the protocol was not used. PREDICTORS: Prescription of the protocol, whereby hemodialysis patients with serum albumin levels ≤3.5g/dL would initiate oral protein supplementation during the dialysis procedure. Sensitivity analyses matched on actual supplement intake during the first 3 study months. Covariates included patient and facility characteristics, which were used to develop the propensity scores and adjust multivariable models. OUTCOMES: All-cause mortality, ascertained though March 2012. RESULTS: Of 6,453 eligible patients in 101 eligible hemodialysis facilities, the protocol was prescribed to 2,700, and 1,278 of these were propensity matched to controls. Mean age was 61 ± 15 (SD) years and median dialysis vintage was 34 months. There were 258 deaths among protocol assignees versus 310 among matched controls during a mean follow-up of 14 months. In matched analyses, protocol prescription was associated with a 29% reduction in the hazard of all-cause mortality (HR, 0.71; 95% CI, 0.58-0.86); adjustment had minimal impact on models. In time-dependent models incorporating change in albumin level, protocol status remained significant but was attenuated in models incorporating a 30-day lag. Similar results were seen in sensitivity analyses of 439 patients receiving supplements who were propensity-matched to controls, with 116 deaths among supplement users versus 140 among controls (HR, 0.79; 95% CI, 0.60-1.05), achieving statistical significance in adjusted models. LIMITATIONS: Observational design, potential residual confounding. CONCLUSIONS: Prescription of an oral nutritional supplement protocol and use of oral protein nutritional supplements during hemodialysis are associated with reduced mortality among in-center maintenance hemodialysis patients, an effect likely not mediated by change in serum albumin levels.
Authors: Jin Hee Jeong; Annabel Biruete; Emily J Tomayko; Pei Tzu Wu; Peter Fitschen; Hae Ryong Chung; Mohamad Ali; Edward McAuley; Bo Fernhall; Shane A Phillips; Kenneth R Wilund Journal: Kidney Int Date: 2019-04-02 Impact factor: 10.612
Authors: Rieko Eriguchi; Yoshitsugu Obi; Connie M Rhee; Jason A Chou; Amanda R Tortorici; Anna T Mathew; Taehee Kim; Melissa Soohoo; Elani Streja; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Hemodial Int Date: 2016-11-25 Impact factor: 1.812
Authors: Mun Sun Choi; Brandon Kistler; Gretchen N Wiese; Elizabeth R Stremke; Amy J Wright; Ranjani N Moorthi; Sharon M Moe; Kathleen M Hill Gallant Journal: J Ren Nutr Date: 2018-08-11 Impact factor: 3.655